Core Insights - Cellectis is focusing on advancing its late-stage allogeneic CAR-T therapies, particularly lasme-cel and eti-cel, with significant clinical trials and partnerships expected to drive growth in 2026 [2][3][4]. Clinical Development - The pivotal Phase 2 trial for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) has commenced, with interim data anticipated in Q4 2026 [2][3]. - Lasme-cel has shown a 68% overall response rate (ORR) and a 56% complete remission rate in early trials, indicating strong efficacy [5]. - The NATHALI-01 trial for eti-cel in relapsed/refractory non-Hodgkin lymphoma (NHL) reported an 88% ORR and a 63% complete remission rate, with further data expected in Q4 2026 [6]. Strategic Partnerships - Cellectis is collaborating with AstraZeneca to develop up to 10 novel cell and gene therapy products targeting high unmet medical needs, leveraging Cellectis' gene editing and manufacturing capabilities [4]. Financial Position - The company projects that its cash reserves will sustain operations into the second half of 2027, indicating a stable financial outlook [8]. Upcoming Events - Cellectis management will participate in the J.P. Morgan Healthcare Conference from January 12-15, 2026, for investor meetings [9].

Shares of Cellectis S.A. (NASDAQ:CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ:ALLO) cited a favorable arbitration outcome for partner Servier in its dispute with Cellectis related to the CAR-T therapy cemacabtagene ansegedleucel (cema-cel).The win reconfirmed Allogene’s full development and commercial control of cema-cel in the U.S., the EU and the U.K., while clearing the path to obtain full global commercialization rights from Servier.Also Read: Why Cellectis Stock Is Trading Higher To ...

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Tuesday.Shares of Lightwave Logic Inc (NASDAQ:LWLG) fell sharply in pre-market trading after the company announced pricing of $35 million public offering of common stock.Lightwave Logic shares dipped 14.5% to $3.22 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Ascent Solar Technologies, Inc. (NASDAQ:ASTI) shares dipped 15.1% to $3.54 in pre-market trading after jumping 34% on Monday. ...

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Tuesday.Shares of Lightwave Logic Inc (NASDAQ:LWLG) fell sharply in pre-market trading after the company announced pricing of $35 million public offering of common stock.Lightwave Logic shares dipped 14.5% to $3.22 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Ascent Solar Technologies, Inc. (NASDAQ:ASTI) shares dipped 15.1% to $3.54 in pre-market trading after jumping 34% on Monday. ...

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeu ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL (“Servier”), relating to the License, Development and Commercialization Agreement ent ...

Core Insights - Cellectis S.A. (CLLS) is a biotech company focused on developing allogeneic CAR-T therapies using its proprietary Transcription Activator-Like Effector Nucleases (TALEN) technology and PulseAgile electroporation [1] Company Overview - Cellectis targets high-unmet medical needs and heavily pretreated patients suffering from B-cell malignancies [1]

Core Insights - Cellectis presented encouraging updated data for its eti-cel product candidate at the 67th Annual Meeting of the American Society of Hematology, showing a promising overall response rate of 88% and a complete response rate of 63% in patients with relapsed/refractory non-Hodgkin lymphoma [1][2][9] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using its gene-editing platform, with a unique allogeneic approach for CAR T immunotherapies [6][7] Clinical Trial Details - The eti-cel candidate is the first allogeneic dual CAR-T targeting CD20 and CD22 simultaneously, currently in Phase 1 of the NATHALI-01 clinical trial for patients who have undergone at least two lines of therapy [2][4] - Preliminary results from the trial indicate an overall response rate of 88% and a complete response rate of 63% based on a sample size of 8 patients [2][9] Future Directions - The company plans to investigate the impact of low dose Interleukin-2 (IL-2) support on the efficacy of eti-cel and will begin recruiting patients for the IL-2 support cohort in Q1 2026 [4][5][9] - Cellectis expects to present the full Phase 1 dataset in 2026 [5][9] Additional Findings - In vivo data suggest that low dose IL-2 support can enhance the expansion and persistence of CAR-T cells, potentially boosting efficacy without increasing toxicity [3][4]

Core Insights - Cellectis has established circular single-stranded DNA (CssDNA) as an efficient non-viral DNA donor template for gene insertion in hematopoietic stem and progenitor cells (HSPCs) [1][5] Gene Editing Technology - Gene editing of HSPCs has the potential for long-term therapeutic benefits, with non-viral DNA templates emerging as promising alternatives to viral vectors like AAV6, which pose safety and efficacy concerns [2] - Cellectis has developed a robust gene insertion process using TALEN technology and CssDNA donor templates, enabling precise integration of large genetic sequences within HSPCs, thus expanding the potential of non-viral gene therapy [3] Efficiency and Application - CssDNA demonstrates 3-5 times higher knock-in efficiency than linear single-stranded DNA (LssDNA), with efficiencies surpassing 40% [9] - CssDNA can insert genes at multiple loci in HSPCs and is applicable to other therapeutic cell types, including primary T cells [9] - Comparative studies indicate that CssDNA-edited HSPCs have a higher propensity to engraft and maintain gene edits in murine models compared to AAV6-edited HSPCs [9] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies, utilizing an allogeneic approach for CAR T immunotherapies in oncology [6] - The company controls the entire cell and gene therapy value chain from start to finish, supported by in-house manufacturing capabilities [6] - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC, and is listed on both the Nasdaq Global Market and Euronext Growth [7]

Core Insights - Cellectis reported promising clinical data for its product candidates lasme-cel (UCART22) and eti-cel (UCART20x22), indicating their potential to improve outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and non-Hodgkin lymphoma (r/r NHL) respectively [3][4][11] Financial Results - As of September 30, 2025, Cellectis had $225 million in cash, cash equivalents, and fixed-term deposits, which is projected to fund operations into the second half of 2027 [4][26] - Consolidated revenues and other income for the nine-month period ended September 30, 2025, were $67.4 million, up from $34.1 million in the same period in 2024, primarily driven by activities related to the AstraZeneca collaboration [29] - Consolidated net loss attributable to shareholders for the nine-month period ended September 30, 2025, was $41.3 million, compared to a loss of $42.7 million in the same period in 2024 [34] Clinical Development - The Phase 1 BALLI-01 study of lasme-cel showed an overall response rate (ORR) of 68% with the Cellectis-manufactured product, and 100% in the target Phase 2 population [6][7] - The first interim analysis for the pivotal Phase 2 BALLI-01 trial is expected in Q4 2026, with a Biologics License Application (BLA) anticipated in 2028 [8][9] - For eti-cel, preliminary data indicated an ORR of 86% and a complete response (CR) rate of 57% in the ongoing study [11] Pipeline Highlights - Lasme-cel is positioned as a potentially transformative therapy for r/r B-ALL, with a projected peak gross sales potential of approximately $700 million by 2035, which could increase to $1.3 billion with label expansions [9] - The company plans to present further updates on eti-cel at the ASH 2025 Annual Meeting [10][14] Innovation and Collaboration - Cellectis is advancing its gene editing technology, including the use of circular single-stranded DNA (CssDNA) as a non-viral template for gene therapy, which has shown high gene insertion frequency in hematopoietic stem and progenitor cells [16][22] - A strategic collaboration with AstraZeneca aims to develop up to 10 novel cell and gene therapy products targeting high unmet medical needs [23]